Eurizon Capital SGR S.p.A. Takes $23.03 Million Position in Biogen Inc. $BIIB

Eurizon Capital SGR S.p.A. bought a new stake in Biogen Inc. (NASDAQ:BIIB) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 130,813 shares of the biotechnology company’s stock, valued at approximately $23,025,000.

Other hedge funds have also made changes to their positions in the company. WPG Advisers LLC raised its stake in shares of Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 117 shares during the period. First Horizon Corp purchased a new position in shares of Biogen in the 4th quarter valued at $30,000. GoalVest Advisory LLC purchased a new position in shares of Biogen in the 4th quarter valued at $35,000. Accredited Wealth Management LLC raised its stake in shares of Biogen by 1,233.3% in the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 185 shares during the period. Finally, Elevation Wealth Partners LLC raised its stake in shares of Biogen by 412.8% in the 4th quarter. Elevation Wealth Partners LLC now owns 200 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 161 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Price Performance

Shares of BIIB stock opened at $196.00 on Friday. The firm has a market cap of $28.94 billion, a P/E ratio of 21.03, a P/E/G ratio of 1.73 and a beta of 0.19. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. Biogen Inc. has a 1-year low of $121.05 and a 1-year high of $205.97. The firm has a fifty day moving average of $186.66 and a two-hundred day moving average of $182.21.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period in the previous year, the business posted $3.02 EPS. The company’s quarterly revenue was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, research analysts anticipate that Biogen Inc. will post 14.18 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Citigroup lifted their price target on shares of Biogen from $190.00 to $200.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. The Goldman Sachs Group lifted their price target on shares of Biogen from $231.00 to $238.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. BMO Capital Markets lifted their price target on shares of Biogen from $165.00 to $196.00 and gave the stock a “market perform” rating in a research note on Friday, February 6th. Royal Bank Of Canada lifted their price target on shares of Biogen from $222.00 to $227.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Weiss Ratings raised shares of Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $215.81.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.